BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,061 filers reported holding BAXTER INTL INC in Q2 2019. The put-call ratio across all filers is 1.42 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $223,587 | -60.0% | 4,908 | -55.3% | 0.01% | -64.7% |
Q4 2022 | $559,257 | +17.5% | 10,972 | +24.1% | 0.03% | +3.0% |
Q3 2022 | $476,000 | +54.5% | 8,838 | +84.1% | 0.03% | +43.5% |
Q2 2022 | $308,000 | -61.2% | 4,801 | -53.1% | 0.02% | -64.1% |
Q1 2022 | $794,000 | -77.4% | 10,238 | -75.0% | 0.06% | -77.1% |
Q4 2021 | $3,518,000 | +104.7% | 40,978 | +91.8% | 0.28% | +100.0% |
Q3 2021 | $1,719,000 | +1085.5% | 21,370 | +1087.2% | 0.14% | +1066.7% |
Q2 2021 | $145,000 | +10.7% | 1,800 | +16.2% | 0.01% | 0.0% |
Q1 2021 | $131,000 | +15.9% | 1,549 | +9.5% | 0.01% | +9.1% |
Q4 2020 | $113,000 | +22.8% | 1,414 | +23.3% | 0.01% | +10.0% |
Q3 2020 | $92,000 | +4.5% | 1,147 | +12.2% | 0.01% | -16.7% |
Q2 2020 | $88,000 | +8.6% | 1,022 | +2.7% | 0.01% | -7.7% |
Q1 2020 | $81,000 | -10.0% | 995 | -8.0% | 0.01% | -18.8% |
Q4 2019 | $90,000 | +4.7% | 1,081 | +9.9% | 0.02% | +14.3% |
Q3 2019 | $86,000 | +34.4% | 984 | +25.8% | 0.01% | +27.3% |
Q1 2019 | $64,000 | +25.5% | 782 | +0.1% | 0.01% | 0.0% |
Q4 2018 | $51,000 | +628.6% | 781 | +705.2% | 0.01% | +450.0% |
Q3 2018 | $7,000 | -46.2% | 97 | -50.0% | 0.00% | -33.3% |
Q2 2018 | $13,000 | – | 194 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |